AbstractBackground and Objectives
Currently, plasma fractionation involves multiple processing steps using established methods such as ethanol precipitation and column chromatography. The known limitations associated with conventional purification techniques, combined with strict regulations on safety and high demand for particular plasma proteins, have resulted in a shortage of plasma-derived therapeutics such as intravenous immunoglobulin G (IgG).Materials and Methods
In this study, IgG was purified from human plasma using Gradiflow technology, an electrophoresis-based separation technology.Results
IgG was isolated from plasma to high purity, with 94 ± 5% recovery in a short processing time.Conclusions
The technology has been shown to be linearly scalable and has the capacity to contribute to increased production of important plasma fraction therapeutics.